Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

TGA acts on melatonin imports with infringement notices totalling $99K

Laboratory testing of several imported unregistered melatonin products has confirmed them to be...

Scientists search for cystitis pain 'off switch'

By targeting certain pain receptors in the bladder, Australian scientists believe that the...

Australia's first cases of H5 avian influenza confirmed

Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...

Content from other channels on our network

CEFC announces new CEO

$32 million investment to create jet fuel from forest waste

Australia's data centre future will be built on concrete — so make it more sustainable

WA wind farm to generate power for 100,000 homes

Ampd launches next-gen battery storage for heavy industries

Blueberry packing house automates sorting after expansion

Suntory Oceania releases 2025 Sustainability Report

AIP to partner with the Packaging Cockpit

WHS guidelines released on risks of AI in the workplace

Lactalis plans to close dairy factory in Gippsland, ADF comments

The Organisations That Will Lead This Sector in Five Years, Are Making Different Decisions Right Now.

Social media behind almost half of racism and discrimination complaints, Ahpra says

OTs, medical students respond to Commonwealth Prac Payment expansion

HIC returns to Sydney in August

New ACMA SMS rules now in force — could patients be missing vital updates?